(RTTNews) - Deciphera Pharmaceuticals, Inc. (DCPH) Monday announced positive top-line results from the pivotal Phase 3 MOTION study of its investigational drug Vimseltinib in patients with ...
According to the Adhishthana framework, stocks typically form a Cakra structure between Phases 4-8, a channel-like setup with an arc that generally carries bullish implications. Once a stock breaks ...
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...
Credit: Getty Images. Tradipitant is a neurokinin-1 receptor antagonist. Tradipitant was found to be superior to placebo in preventing vomiting associated with motion sickness, according to results ...
“We think so much of our Phase III Supercars that we guarantee they will turn at least 120 mph in 11.50 seconds or better with an approved driver on an AHRA or NHRA-sanctioned drag strip.” That was ...
MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas. Background: Tenosynovial giant cell tumor (TGCT) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results